Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 18;27(1):108630.
doi: 10.1016/j.isci.2023.108630. eCollection 2024 Jan 19.

Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma

Chen Jiang  1   2 , Li-Yun Huang  1   2 , Ji-Hao Zhou  3 , Zhi-Ming Li  1   4 , Yu Wang  1   4 , Shuo Li  1   2 , Jian-Chang Fu  1   2 , Qi-Tao Huang  1   2 , Qin Yan  1   2 , Yu-Yuan Huang  5 , Min Zuo  3 , Shimin Hu  6 , Robert Peter Gale  7 , Yang Liang  1   8 , Jing-Ping Yun  1   2 , Yu-Hua Huang  1   2
Affiliations

Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma

Chen Jiang et al. iScience. .

Abstract

The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receiving ABVD therapy and demonstrated EBV-infection in their lymphoma cells with EBV-encoded small RNAs (EBERs) in situ hybridization. Subjects were divided into training and validation datasets. As data from the training dataset suggested EBERs-positivity was the only independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), we developed corresponding prognostic models based on it. Our models showed excellent performance in both training and validation cohort. These data indicate the close association of EBV infection and the outcomes of persons with NScHL receiving ABVD. Additionally, our newly developed models should help physicians estimate prognosis and select individualized therapy.

Keywords: Cancer; Immunology; Public health.

PubMed Disclaimer

Conflict of interest statement

R.P.G. is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.

Figures

None
Graphical abstract
Figure 1
Figure 1
CONSORT flow diagram
Figure 2
Figure 2
EBV-based prognostic model (A) PFS and OS model; (B) K-M plot of PFS in the training cohort; (C) K-M plot of OS in the training cohort; (D) K-M plot of PFS in the validation cohort; (E) K-M plot of OS in the validation cohort. ∗ IPS was calculated for stage III/IV disease. Subjects with stage III/IV disease, IPS ≥4 were considered to have this risk factor and others not.
See this image and copyright information in PMC

References

    1. Murray P.G., Young L.S. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019;134:591–596. - PubMed
    1. Swerdlow S.H.C.E.,H.N., Jaffe E.S., Pileri S.A., Stein H., Thiele J. 4th ed. 2017. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised; pp. 424–430.
    1. Lee J.H., Kim Y., Choi J.W., Kim Y.S. Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis. Arch. Med. Res. 2014;45:417–431. - PubMed
    1. Koh Y.W., Han J.H., Yoon D.H., Suh C., Huh J. Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. Hematol. Oncol. 2018;36:182–188. - PubMed
    1. Cheriyalinkal Parambil B., Narula G., Dhamne C., Roy Moulik N., Shet T., Shridhar E., Gujral S., Shah S., Laskar S., Khanna N., Banavali S. Assessment of tumor Epstein-Barr Virus status and its impact on outcomes in intermediate and high-risk childhood classic Hodgkin Lymphoma treated at a tertiary cancer center in India. Leuk. Lymphoma. 2020;61:3217–3225. - PubMed